Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Baxter Establishes Cambridge R&D Site …
by Lisa M. Jarvis
October 6, 2014
| A version of this story appeared in
Volume 92, Issue 40
In advance of spinning off its biopharmaceuticals business, Baxter is establishing an R&D center in Cambridge, Mass., for the new company. To become stand-alone in mid-2015, the new firm, Baxalta, will focus on hematology, immunology, gene therapy, and biosimilars. Some 400 scientists will be based at the R&D center, alongside Baxalta’s business development, oncology, and biosimilars teams. Baxalta will continue R&D in Vienna, Austria, but some R&D positions from California and Austria will relocate to Massachusetts.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter